Adamas Pharmaceuticals Inc. (ADMS) 14.83 $ADMS
Adamas Pharmaceuticals to Present at 2014 Credit Suisse Healthcare Conference
GlobeNewswire - Wed Nov 05, 3:02PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the 2014 Credit Suisse Healthcare Conference in Phoenix, AZ on Tuesday, November 11, 2014 at 7:30 AM Mountain Time.
ADMS: 14.83 (+0.25)
Adamas Pharma misses by $0.13, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:44PM CST
ADMS: 14.83 (+0.25)
Adamas Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 3:03PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported a net loss attributable to common stockholders of $9.6 million, or $0.57 per share, for the quarter ended September 30, 2014. In the same period last year, the company reported a net loss attributable to common stockholders of $3.4 million, or $0.36 per share. Adamas ended the current quarter with $137.5 million in cash and cash equivalents, compared to $85.6 million at December 31, 2013.
ADMS: 14.83 (+0.25)
Adamas Pharmaceuticals Expands Its Phase 3 Program With ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) in Patients With Parkinson's Disease
GlobeNewswire - Tue Oct 28, 3:01PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it has initiated an additional Phase 3 safety and efficacy study evaluating ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. ADS-5102, an investigational agent, is a high dose, controlled-release version of amantadine HCl administered once daily at bedtime.
ADMS: 14.83 (+0.25)
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 305.43 (-12.55), MNOV: 3.07 (+0.03), CHTP: 6.52 (-0.03), ADMS: 14.83 (+0.25), ACOR: 33.47 (-0.26), BCLI: 3.47 (-0.11), BSX: 13.36 (-0.05), IPXL: 28.86 (-0.20), AVNR: 13.13 (-0.01), ACAD: 27.14 (-0.76), CVTS: (), MRK: 59.07 (-0.47), TEVA: 57.07 (-0.10), PRTA: 21.53 (-0.27), PRAN: 1.73 (+0.01), FOLD: 5.69 (-0.18), CUR: 2.86 (+0.05)
OTC Daily Alert Stock Watch - Adamas Pharmaceuticals, Inc., (NASDAQ: ADMS)
WorldStockWire - Sat Oct 18, 11:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ADMS: 14.83 (+0.25)
5 Big-Volume Stocks to Trade for Big Breakouts
at The Street - Thu Oct 02, 8:20AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
MDVN: 106.90 (-0.31), RCAP: 12.09 (+0.74), ADMS: 14.83 (+0.25), TRGP: 115.90 (+0.46), NRG: 31.31 (-0.24)
Adamas Pharmaceuticals Announces Management Changes
GlobeNewswire - Wed Aug 13, 3:05PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced changes to its management team.
ADMS: 14.83 (+0.25)
Adamas Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 3:44PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported net income attributable to common stockholders of $16.4 million, or $0.88 per share on a fully diluted basis, for the quarter ended June 30, 2014. In the same period last year, the company reported a net loss attributable to common stockholders of $3.4 million, or $0.35 per share on a fully diluted basis. The difference between the two periods was primarily the result of the recognition of revenue associated with the collaboration with Forest Laboratories, Inc. (acquired by Actavis plc in July 2014).
ADMS: 14.83 (+0.25), FRX: 99.00 (-0.77)
Adamas Pharmaceuticals receives US Patent No. 8,796,337 for ADS-5102 and amantadine product candidates
M2 - Wed Aug 06, 5:48AM CDT
Specialist pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) reported on Tuesday the receipt of the US Patent No. 8,796,337, entitled "Composition and Method For Treating Neurological Disease" from the US Patent and Trademark Office (USPTO).
ADMS: 14.83 (+0.25)
United States Patent Issued to Adamas Pharmaceuticals
GlobeNewswire - Tue Aug 05, 3:08PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS), today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,796,337, entitled "Composition and Method For Treating Neurological Disease." The claims of this patent are directed towards methods for treating human subjects with amantadine therapy, including Adamas' lead product candidate ADS-5102 and similar amantadine-based products.
ADMS: 14.83 (+0.25)
Adamas Pharmaceuticals, Inc. (ADMS) in Focus: Stock Rises 7.04% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 7:44AM CDT
Adamas Pharmaceuticals, Inc. (ADMS) was a big mover last session, as the company saw its shares rise 7% on the day.
MNK: 88.11 (+1.15), AKRX: 38.21 (+0.53), ADMS: 14.83 (+0.25), RDY: 56.03 (-0.22)
Forest Laboratories Nabs Pediatric Exclusivity for Namenda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 12:20PM CDT
With an additional six months of pediatric exclusivity in the U.S., generic versions of Forest's (FRX) Namenda IR will now enter the market in Jul 2015.
ACT: 243.77 (+2.14), GILD: 102.06 (-2.14), ADMS: 14.83 (+0.25), FRX: 99.00 (-0.77)
Adamas Pharmaceuticals To Present At JMP Securities Healthcare Conference 2014
PR Newswire - Mon Jun 16, 3:01PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the JMP Securities Healthcare Conference 2014 in New York on Tuesday, June 24, 2014 at 1:00 PM Eastern Standard Time.
ADMS: 14.83 (+0.25)
Will Forest Labs Retain Namenda Market Share? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 11:00AM CDT
Forest Laboratories, Inc. (FRX) has postponed the final phase of switching to late 2014 and intends to continue marketing Namenda IR till the fall of 2014.
ACT: 243.77 (+2.14), ADMS: 14.83 (+0.25), ANIP: 53.95 (+2.48), FRX: 99.00 (-0.77)
Steve Bederman Thought-Technology Leader is Hosting the 2nd in a Webinar Series, "Modernize Your Marketing with the Most Advanced Messaging Solutions in the Marketplace"
PRWeb - Thu Apr 25, 1:07AM CDT
Communication and technology are forever evolving and changing. In the United States alone, approximately 91% of the population has their mobile device within reach 24/7. Additionally, the average user looks at their phone 150 times a day.
ADMS: 14.83 (+0.25)
Adamas Pharmaceuticals to Present at 2014 Credit Suisse Healthcare Conference
GlobeNewswire - Wed Nov 05, 3:02PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the 2014 Credit Suisse Healthcare Conference in Phoenix, AZ on Tuesday, November 11, 2014 at 7:30 AM Mountain Time.
ADMS: 14.83 (+0.25)
Adamas Pharma misses by $0.13, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:44PM CST
ADMS: 14.83 (+0.25)
Adamas Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 3:03PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported a net loss attributable to common stockholders of $9.6 million, or $0.57 per share, for the quarter ended September 30, 2014. In the same period last year, the company reported a net loss attributable to common stockholders of $3.4 million, or $0.36 per share. Adamas ended the current quarter with $137.5 million in cash and cash equivalents, compared to $85.6 million at December 31, 2013.
ADMS: 14.83 (+0.25)
Adamas Pharmaceuticals Expands Its Phase 3 Program With ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) in Patients With Parkinson's Disease
GlobeNewswire - Tue Oct 28, 3:01PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it has initiated an additional Phase 3 safety and efficacy study evaluating ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. ADS-5102, an investigational agent, is a high dose, controlled-release version of amantadine HCl administered once daily at bedtime.
ADMS: 14.83 (+0.25)
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 305.43 (-12.55), MNOV: 3.07 (+0.03), CHTP: 6.52 (-0.03), ADMS: 14.83 (+0.25), ACOR: 33.47 (-0.26), BCLI: 3.47 (-0.11), BSX: 13.36 (-0.05), IPXL: 28.86 (-0.20), AVNR: 13.13 (-0.01), ACAD: 27.14 (-0.76), CVTS: (), MRK: 59.07 (-0.47), TEVA: 57.07 (-0.10), PRTA: 21.53 (-0.27), PRAN: 1.73 (+0.01), FOLD: 5.69 (-0.18), CUR: 2.86 (+0.05)
OTC Daily Alert Stock Watch - Adamas Pharmaceuticals, Inc., (NASDAQ: ADMS)
WorldStockWire - Sat Oct 18, 11:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ADMS: 14.83 (+0.25)
5 Big-Volume Stocks to Trade for Big Breakouts
at The Street - Thu Oct 02, 8:20AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
MDVN: 106.90 (-0.31), RCAP: 12.09 (+0.74), ADMS: 14.83 (+0.25), TRGP: 115.90 (+0.46), NRG: 31.31 (-0.24)
Adamas Pharmaceuticals Announces Management Changes
GlobeNewswire - Wed Aug 13, 3:05PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced changes to its management team.
ADMS: 14.83 (+0.25)
Adamas Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 3:44PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported net income attributable to common stockholders of $16.4 million, or $0.88 per share on a fully diluted basis, for the quarter ended June 30, 2014. In the same period last year, the company reported a net loss attributable to common stockholders of $3.4 million, or $0.35 per share on a fully diluted basis. The difference between the two periods was primarily the result of the recognition of revenue associated with the collaboration with Forest Laboratories, Inc. (acquired by Actavis plc in July 2014).
ADMS: 14.83 (+0.25), FRX: 99.00 (-0.77)
Adamas Pharmaceuticals receives US Patent No. 8,796,337 for ADS-5102 and amantadine product candidates
M2 - Wed Aug 06, 5:48AM CDT
Specialist pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) reported on Tuesday the receipt of the US Patent No. 8,796,337, entitled "Composition and Method For Treating Neurological Disease" from the US Patent and Trademark Office (USPTO).
ADMS: 14.83 (+0.25)
United States Patent Issued to Adamas Pharmaceuticals
GlobeNewswire - Tue Aug 05, 3:08PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS), today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,796,337, entitled "Composition and Method For Treating Neurological Disease." The claims of this patent are directed towards methods for treating human subjects with amantadine therapy, including Adamas' lead product candidate ADS-5102 and similar amantadine-based products.
ADMS: 14.83 (+0.25)
Adamas Pharmaceuticals, Inc. (ADMS) in Focus: Stock Rises 7.04% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 7:44AM CDT
Adamas Pharmaceuticals, Inc. (ADMS) was a big mover last session, as the company saw its shares rise 7% on the day.
MNK: 88.11 (+1.15), AKRX: 38.21 (+0.53), ADMS: 14.83 (+0.25), RDY: 56.03 (-0.22)
Forest Laboratories Nabs Pediatric Exclusivity for Namenda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 12:20PM CDT
With an additional six months of pediatric exclusivity in the U.S., generic versions of Forest's (FRX) Namenda IR will now enter the market in Jul 2015.
ACT: 243.77 (+2.14), GILD: 102.06 (-2.14), ADMS: 14.83 (+0.25), FRX: 99.00 (-0.77)
Adamas Pharmaceuticals To Present At JMP Securities Healthcare Conference 2014
PR Newswire - Mon Jun 16, 3:01PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the JMP Securities Healthcare Conference 2014 in New York on Tuesday, June 24, 2014 at 1:00 PM Eastern Standard Time.
ADMS: 14.83 (+0.25)
Will Forest Labs Retain Namenda Market Share? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 11:00AM CDT
Forest Laboratories, Inc. (FRX) has postponed the final phase of switching to late 2014 and intends to continue marketing Namenda IR till the fall of 2014.
ACT: 243.77 (+2.14), ADMS: 14.83 (+0.25), ANIP: 53.95 (+2.48), FRX: 99.00 (-0.77)
Steve Bederman Thought-Technology Leader is Hosting the 2nd in a Webinar Series, "Modernize Your Marketing with the Most Advanced Messaging Solutions in the Marketplace"
PRWeb - Thu Apr 25, 1:07AM CDT
Communication and technology are forever evolving and changing. In the United States alone, approximately 91% of the population has their mobile device within reach 24/7. Additionally, the average user looks at their phone 150 times a day.
ADMS: 14.83 (+0.25)
